Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1127)	5/4/1998 11:47:00 AM
From: JOEBT1	Read Replies (1) \| Respond to of 2742

Rick--I've been tracking CTRX for a couple of years. It has a drug called IGF-BP3 which is a insulin growth factor. The drug is identical to Cephalon's drug for MS which is up for FDA review. Cephalon's drug has side effects which limit dosage ( and therefore, efficacy ). CTRX's can get 32 times the dosage of Cephalon' drug without harmful side effects. BP3 is a molecule that enables greater dosages of IGF without harmful side effects. IGF-BP3 is a hormone that occurs in the body. It's been proven to stimulate muscle and bone growth and also stimulates production of interleukin-2 by 280% and a 25 to 90% increase in interferon gamma (see today's press release). IMHO I think they may a blockbuster drug but they need money or a partner. Would appreciate your views.